Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Qualigen Therapeutics ( (QLGN) ) is now available.
On August 21, 2025, Qualigen Therapeutics, Inc. amended its secured promissory note with Marizyme, Inc., increasing the principal balance to $4,451,462.18. This agreement includes a security interest in Marizyme’s assets and a conditional forbearance from demanding payment for one year, impacting the company’s financial arrangements and stakeholder interests.
Spark’s Take on QLGN Stock
According to Spark, TipRanks’ AI Analyst, QLGN is a Underperform.
Qualigen Therapeutics’ overall stock score is low due to significant financial challenges, including declining revenue, substantial losses, and financial instability. The bearish technical analysis further dampens the outlook. However, recent corporate events like strategic investments and leadership changes provide a slight positive outlook on future potential improvements.
To see Spark’s full report on QLGN stock, click here.
More about Qualigen Therapeutics
Average Trading Volume: 837,671
Technical Sentiment Signal: Sell
Current Market Cap: $3.14M
For an in-depth examination of QLGN stock, go to TipRanks’ Overview page.